Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download whitepaper

Precision medicine in brain tumors 2025: Diagnostics and therapeutic innovation

An evidence-based overview of the advances shaping CNS oncology

Progress in precision medicine for brain tumors has been slow compared with other cancers. Outcomes for glioblastoma and high-grade gliomas remain poor, and many targeted and immunotherapy trials have shown limited benefit. Key challenges include tumor heterogeneity, slow diagnostic timelines, difficulty delivering therapies across the blood brain barrier, and small, highly variable patient populations.

Over the last two years, however, new momentum has emerged. Rapid genomic and molecular profiling approaches are improving the speed and accuracy of molecular tumour characterization. In parallel, adaptive platform trials and genomically informed screening are helping sponsors evaluate targeted agents, cell therapies, and gene-based approaches more efficiently across rare and molecularly defined subgroups.

This whitepaper provides an up-to-date overview of:

  • Advances in molecular diagnostics for CNS tumors
  • Recent precision therapies showing activity in genetic subgroups
  • How adaptive and platform trial designs are reducing screen failures and improving enrollment in CNS oncology
  • Key implications for early-phase development, including faster patient stratification and clearer early efficacy signals

This report is designed for clinical development teams, biotech leaders, and anyone working at the intersection of genomics, diagnostics, and CNS oncology. It summarizes the latest evidence shaping precision medicine in brain tumors and the practical shifts underway in early clinical research.

Download the whitepaper to understand the latest developments in diagnostics, trial design, and emerging therapies in CNS oncology.

BTcovers